QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics…
By David Bautz, PhD
NASDAQ:QLGN
READ THE FULL QLGN RESEARCH REPORT
Qualigen Surges 80% As QN-302 Shows Potential Preclinical Mechanism Of Action Against Prostate, Pancreatic Cancers
Qualigen Therapeutics Inc (NASDAQ: QLGN) shares are surging after highlighting posters at the American Association of Cancer Research (AACR).
Qualigen Therapeutics Highlights 3 Poster Presentations On Its QN-302 At American Association Of Cancer Research Apr. 13, 2022 Between 9am-12pm EDT
Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers
CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified
Qualigen Therapeutics Extends Research Agreement With University Of Louisville Research Foundation On RAS Program Through Q1 Of 2023
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing
44 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Indonesia Energy Corporation Limited (NYSE: INDO) shares climbed 66.7% to $12.55 following a 16% surge on Wednesday.
32 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Imperial Petroleum Inc. (NASDAQ: IMPP) rose 45.1% to $1.64 in pre-market trading after gaining around 41% on Wednesday.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Qualigen Therapeutics CEO Michael Poirier Issues Letter To Shareholders
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation and diagnostics, today issues the